Patient population
vessel occlusion, Erasmus, CHC, MR, acute ischemic stroke
In this sub-study, we used data of patients included in the MR CLEAN-NO IV trial. This was an open-label, multicenter, randomized trial in Europe that assessed the value of IVT before endovascular treatment (EVT) of patients with acute ischemic stroke due to a proximal intracranial large vessel occlusion. Patients above the age of 18 years, who were eligible for IVT with alteplase within 4.5 hours of symptom onset and presented directly at a center providing both treatments were randomized to receive either EVT alone or EVT after IVT. Information regarding the inclusion and exclusion criterion employed by the trial have been published previously.The MR CLEAN-NO IV protocol was approved in the Netherlands by the central medical ethics committee and research board of the Erasmus MC University Medical Center, Rotterdam, the Netherlands (MEC-2017-368) before start of the trial. In France, the study was approved by the Comité de Protection des Personnes, Ile de France IV (ID-RCB: 2018-A00764-51). In Belgium, the study was approved by the Central Ethics Committee Research UZ/KU Leuven, Belgian Registration Number: B322201939935, as well as the Comité d’Ethique Medicale, CHC, Liège, Belgium (study number: 19/20/987). The study was conducted according to the principles of the Declaration of Helsinki (7th revision, October 2013), ICH-GCP, the Dutch Medical Research Involving Human Subjects Act (WMO) and when applicable in accordance with regulations of other countries with participating centers. The trial protocol, including protocol version and amendments, can be found on the website 